Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Sponsor: Cui Yimin
This observational or N/A phase trial investigates Capecitabine and Drug-Related Side Effects and Adverse Reactions and is currently ongoing. Cui Yimin leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cui Yimin
For direct contact, visit the study record on ClinicalTrials.gov .